Adalimumab vs. Conventional Immunosuppression for Corticosteroid-sparing for Uveitis (ADVISE) Trial

Recruiting
99 years or below
All
1 Location

Brief description of study

The ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial is a randomized, comparative effectiveness trial comparing adalimumab to conventional agent immunosuppression for patients with non-infectious, intermediate, posterior, and panuveitides. Scheie Eye Institute, the Department of Ophthalmology, University of Pennsylvania will not enroll any patients under 18 years of age.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: uveitis
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 832873

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.